Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)

With the spotlight firmly on Covid variants, it’s easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. It’s where the largest revolutions will happen. It’s the epicenter of the most important […]

The Race is Heating Up in the $30-plus Billion NASH Treatment Space (MDGL, ATRX, VKTX, ARWR, GALT, MTCR, ICPT, GILD)

The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as big as $20-35 billion annually by midway through this decade. NASH is […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gets A HIV Boost

Boston, MA 10/31/2013 (wallstreetpr) – Hundred Billion Dollar Biopharmaceutical Company Gilead Sciences, Inc. (NASDAQ:GILD) has come out with stellar results which look to have received a booster shot from sale of its HIV drugs. Company has been able to increase its revenues by 15% to $2.78 billion. This is almost 60 million dollars more than what analysts […]

Gilead Sciences, Inc. (NASDAQ:GILD): FDA Advisory Backs Hepatitis C Drug, Sales Projected At $1.73 Billion

Boston, MA 10/28/2013 (wallstreetpr) – A panel of the U.S. Food and Drug Administration Advisory Committee has recommended for approval of Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis C drug sofosbuvir. FDA is not bound to follow the Advisory Committee’s recommendation; however, it has typically done so in the past. This drug is considered more effective than any […]